Developing
Biosimilars and CAR-T Cell pharmaceuticals
What is a Biosimilar medicine?
A medicine developed to be similar to an
already existing and approved medicine
which patent has expired and therefore can
be sold at significantly lower prices.
Biosimilars are driven by a social agenda to
make key life-saving drugs affordable to the
general public.
Biosimilars Vs. Generic medicines
Unlike Biosimilars, Generic drugs are based on Chemical or Small Molecules based active ingredients which are easy to synthesize and formulate with vast knowhow available in public domain.
Such medicines (known as Biological drugs) are developed under significant trade secrets, have very little information in public domain and require significant knowhow and scientific skill to achieve successful replication.
Due to the high costs of Biological drugs:
- 20% of patients choose to skip a dose every other month.
- Cancer patients are 2.5 times more likely to file for bankruptcy.
- 30% of patients are completely drained from their savings.
- Millions cannot afford even to start treatment at any.
level Fred Hutchinson, Cancer Research Center – Seattle USA
CAR-T Cell Therapy
2017, Emily Whitehead (USA), was the first Leukemia patient treated with CAR-T cell therapy. She was completely cured with total remission.
BIOCURE ANNOUNCED a BREAKTHROUGH PRE-CLINICAL TRIAL RESULTS FOR CAR-T CELLS TREATMENT OF ACUTE LEUKEMIA
Trial results demonstrated zero toxicity of the reengineered BioCure CAR-T Cells within 7 and 28 days from their injection into mice.
Our Social Agenda
Affordable Key
Pharmaceuticals
Patent expiration of major Biological drugs
during the coming years creates an early
market opportunities for Biosimilars.
Our agenda is to provide as many Biosimilar
products as possible to leverage BioCure
unique scientific knowhow and skills to
drive social equality via affordable
medicines.